Does the media refer more to ZLAB or APGE?

In the previous week, Apogee Therapeutics had 2 more articles in the media than Zai Lab. MarketBeat recorded 12 mentions for Apogee Therapeutics and 10 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.56 beat Apogee Therapeutics' score of 0.13 indicating that Zai Lab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, IMVT or ZLAB?

Zai Lab has higher revenue and earnings than Immunovant. Zai Lab is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.82 N/A Zai Lab $460.16M 6.42 -$175.54M -$1.71 N/A

Is IMVT or ZLAB more profitable?

Immunovant has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Zai Lab -41.86% -27.43% -16.72%

Does the media prefer IMVT or ZLAB?

In the previous week, Zai Lab had 2 more articles in the media than Immunovant. MarketBeat recorded 10 mentions for Zai Lab and 8 mentions for Immunovant. Immunovant's average media sentiment score of 1.04 beat Zai Lab's score of 0.56 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, TGTX or ZLAB?

TG Therapeutics has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $799.54M 9.33 $447.18M $2.74 17.79 Zai Lab $460.16M 6.42 -$175.54M -$1.71 N/A

Is TGTX or ZLAB more profitable?

TG Therapeutics has a net margin of 55.22% compared to Zai Lab's net margin of -41.86%. TG Therapeutics' return on equity of 73.49% beat Zai Lab's return on equity. Company Net Margins Return on Equity Return on Assets TG Therapeutics 55.22% 73.49% 34.14% Zai Lab -41.86% -27.43% -16.72%

Does the media prefer TGTX or ZLAB?

In the previous week, Zai Lab had 2 more articles in the media than TG Therapeutics. MarketBeat recorded 10 mentions for Zai Lab and 8 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.99 beat Zai Lab's score of 0.56 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, PCVX or ZLAB?

Zai Lab has higher revenue and earnings than Vaxcyte. Zai Lab is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$7.63 N/A Zai Lab $460.16M 6.42 -$175.54M -$1.71 N/A

Is PCVX or ZLAB more profitable?

Vaxcyte has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -37.56% -33.62% Zai Lab -41.86% -27.43% -16.72%

Does the media prefer PCVX or ZLAB?

In the previous week, Zai Lab had 3 more articles in the media than Vaxcyte. MarketBeat recorded 10 mentions for Zai Lab and 7 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.13 beat Zai Lab's score of 0.56 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, IBRX or ZLAB?

Zai Lab has higher revenue and earnings than ImmunityBio. Zai Lab is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 70.82 -$351.40M -$0.97 N/A Zai Lab $460.16M 6.42 -$175.54M -$1.71 N/A

Is IBRX or ZLAB more profitable?

Zai Lab has a net margin of -41.86% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Zai Lab's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -598.55% N/A -51.65% Zai Lab -41.86% -27.43% -16.72%

Does the media prefer IBRX or ZLAB?

In the previous week, Zai Lab had 6 more articles in the media than ImmunityBio. MarketBeat recorded 10 mentions for Zai Lab and 4 mentions for ImmunityBio. Zai Lab's average media sentiment score of 0.56 beat ImmunityBio's score of 0.50 indicating that Zai Lab is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Zai Lab 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zai Lab (ZLAB) Competitors

$25.95 -0.08 (-0.31%)

Closing price 04:00 PM Eastern

Extended Trading

$25.94 -0.01 (-0.05%)

As of 07:57 PM Eastern

Compare

ZLAB vs. APGE, IMVT, TGTX, PCVX, and IBRX

Should you buy Zai Lab stock or one of its competitors? Zai Lab's main competitors and comparable companies include Apogee Therapeutics (APGE), Immunovant (IMVT), TG Therapeutics (TGTX), Vaxcyte (PCVX), and ImmunityBio (IBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Zai Lab compare to Apogee Therapeutics?

Zai Lab (NASDAQ:ZLAB) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Apogee Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Apogee Therapeutics	N/A	-29.88%	-28.08%

In the previous week, Apogee Therapeutics had 2 more articles in the media than Zai Lab. MarketBeat recorded 12 mentions for Apogee Therapeutics and 10 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.56 beat Apogee Therapeutics' score of 0.13 indicating that Zai Lab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zai Lab currently has a consensus target price of $40.20, indicating a potential upside of 54.91%. Apogee Therapeutics has a consensus target price of $124.43, indicating a potential downside of 7.52%. Given Zai Lab's stronger consensus rating and higher probable upside, equities analysts plainly believe Zai Lab is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.20

Zai Lab has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

Zai Lab has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	6.42	-$175.54M	-$1.71	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 4.9% of Zai Lab shares are held by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Zai Lab beats Apogee Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Zai Lab compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Zai Lab (NASDAQ:ZLAB) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Zai Lab has higher revenue and earnings than Immunovant. Zai Lab is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Zai Lab	$460.16M	6.42	-$175.54M	-$1.71	N/A

Immunovant has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 1.9% of Immunovant shares are owned by insiders. Comparatively, 4.9% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Zai Lab had 2 more articles in the media than Immunovant. MarketBeat recorded 10 mentions for Zai Lab and 8 mentions for Immunovant. Immunovant's average media sentiment score of 1.04 beat Zai Lab's score of 0.56 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant presently has a consensus target price of $44.00, suggesting a potential upside of 5.21%. Zai Lab has a consensus target price of $40.20, suggesting a potential upside of 54.91%. Given Zai Lab's stronger consensus rating and higher possible upside, analysts clearly believe Zai Lab is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Immunovant has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Zai Lab	-41.86%	-27.43%	-16.72%

Summary

Zai Lab beats Immunovant on 11 of the 16 factors compared between the two stocks.

How does Zai Lab compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Zai Lab (NASDAQ:ZLAB) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by insiders. Comparatively, 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

TG Therapeutics has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$799.54M	9.33	$447.18M	$2.74	17.79
Zai Lab	$460.16M	6.42	-$175.54M	-$1.71	N/A

TG Therapeutics currently has a consensus price target of $63.00, indicating a potential upside of 29.26%. Zai Lab has a consensus price target of $40.20, indicating a potential upside of 54.91%. Given Zai Lab's stronger consensus rating and higher possible upside, analysts clearly believe Zai Lab is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Zai Lab had 2 more articles in the media than TG Therapeutics. MarketBeat recorded 10 mentions for Zai Lab and 8 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.99 beat Zai Lab's score of 0.56 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a net margin of 55.22% compared to Zai Lab's net margin of -41.86%. TG Therapeutics' return on equity of 73.49% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Zai Lab	-41.86%	-27.43%	-16.72%

TG Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Summary

TG Therapeutics beats Zai Lab on 13 of the 17 factors compared between the two stocks.

How does Zai Lab compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Zai Lab (NASDAQ:ZLAB) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Vaxcyte has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Zai Lab	-41.86%	-27.43%	-16.72%

Vaxcyte has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by insiders. Comparatively, 4.9% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Vaxcyte presently has a consensus target price of $86.00, indicating a potential upside of 48.10%. Zai Lab has a consensus target price of $40.20, indicating a potential upside of 54.91%. Given Zai Lab's stronger consensus rating and higher possible upside, analysts plainly believe Zai Lab is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Zai Lab has higher revenue and earnings than Vaxcyte. Zai Lab is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Zai Lab	$460.16M	6.42	-$175.54M	-$1.71	N/A

In the previous week, Zai Lab had 3 more articles in the media than Vaxcyte. MarketBeat recorded 10 mentions for Zai Lab and 7 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.13 beat Zai Lab's score of 0.56 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zai Lab beats Vaxcyte on 10 of the 16 factors compared between the two stocks.

How does Zai Lab compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Zai Lab (NASDAQ:ZLAB) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Zai Lab had 6 more articles in the media than ImmunityBio. MarketBeat recorded 10 mentions for Zai Lab and 4 mentions for ImmunityBio. Zai Lab's average media sentiment score of 0.56 beat ImmunityBio's score of 0.50 indicating that Zai Lab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Zai Lab	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 66.1% of ImmunityBio shares are held by insiders. Comparatively, 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Zai Lab has higher revenue and earnings than ImmunityBio. Zai Lab is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	70.82	-$351.40M	-$0.97	N/A
Zai Lab	$460.16M	6.42	-$175.54M	-$1.71	N/A

Zai Lab has a net margin of -41.86% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Zai Lab	-41.86%	-27.43%	-16.72%

ImmunityBio has a beta of 0.03, meaning that its share price is 97% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

ImmunityBio presently has a consensus target price of $14.20, indicating a potential upside of 87.58%. Zai Lab has a consensus target price of $40.20, indicating a potential upside of 54.91%. Given ImmunityBio's higher probable upside, equities analysts clearly believe ImmunityBio is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Zai Lab beats ImmunityBio on 9 of the 16 factors compared between the two stocks.

Get Zai Lab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZLAB vs. The Competition

Export

Metric	Zai Lab	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.96B	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.70%	2.57%	10.45%
P/E Ratio	-15.18	10.67	269.06	25.28
Price / Sales	6.42	1,275.04	592.96	87.71
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	4.86	16.78	12.91	6.24
Net Income	-$175.54M	-$13.32M	$3.45B	$347.60M
7 Day Performance	11.28%	1.74%	1.12%	1.07%
1 Month Performance	34.46%	1.60%	1.79%	1.03%
1 Year Performance	-25.71%	56.43%	67.69%	20.77%

Zai Lab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZLAB Zai Lab	2.5422 of 5 stars	$25.95 -0.3%	$40.20 +54.9%	-26.9%	$2.96B	$460.16M	N/A	1,784	News Coverage Insider Trade Gap Down
APGE Apogee Therapeutics	1.0022 of 5 stars	$134.11 +0.0%	$121.25 -9.6%	+259.8%	$8.30B	N/A	N/A	91	Earnings Report Analyst Downgrade
IMVT Immunovant	1.6561 of 5 stars	$38.51 -0.3%	$42.11 +9.4%	+163.2%	$7.97B	N/A	N/A	120	Positive News
TGTX TG Therapeutics	4.3765 of 5 stars	$46.17 -11.3%	$58.50 +26.7%	+72.0%	$7.96B	$616.29M	16.14	290	High Trading Volume
PCVX Vaxcyte	2.2273 of 5 stars	$53.53 -1.0%	$86.00 +60.7%	+86.6%	$7.81B	N/A	N/A	160	Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZLAB) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zai Lab (ZLAB) Competitors

ZLAB vs. APGE, IMVT, TGTX, PCVX, and IBRX

How does Zai Lab compare to Apogee Therapeutics?

Summary

How does Zai Lab compare to Immunovant?

Summary

How does Zai Lab compare to TG Therapeutics?

Summary

How does Zai Lab compare to Vaxcyte?

Summary

How does Zai Lab compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZLAB vs. The Competition

Zai Lab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zai Lab (ZLAB) Competitors

ZLAB vs. APGE, IMVT, TGTX, PCVX, and IBRX

How does Zai Lab compare to Apogee Therapeutics?

Is ZLAB or APGE more profitable?

Does the media refer more to ZLAB or APGE?

Do analysts prefer ZLAB or APGE?

Which has more risk and volatility, ZLAB or APGE?

Which has higher valuation and earnings, ZLAB or APGE?

Do institutionals & insiders believe in ZLAB or APGE?

Summary

How does Zai Lab compare to Immunovant?

Which has stronger valuation and earnings, IMVT or ZLAB?

Which has more risk & volatility, IMVT or ZLAB?

Do insiders and institutionals hold more shares of IMVT or ZLAB?

Does the media prefer IMVT or ZLAB?

Do analysts rate IMVT or ZLAB?

Is IMVT or ZLAB more profitable?

Summary

How does Zai Lab compare to TG Therapeutics?

Do insiders & institutionals believe in TGTX or ZLAB?

Which has better valuation and earnings, TGTX or ZLAB?

Do analysts rate TGTX or ZLAB?

Does the media prefer TGTX or ZLAB?

Is TGTX or ZLAB more profitable?

Which has more risk and volatility, TGTX or ZLAB?

Summary

How does Zai Lab compare to Vaxcyte?

Is PCVX or ZLAB more profitable?

Which has more volatility and risk, PCVX or ZLAB?

Do institutionals & insiders believe in PCVX or ZLAB?

Do analysts prefer PCVX or ZLAB?

Which has preferable valuation and earnings, PCVX or ZLAB?

Does the media prefer PCVX or ZLAB?

Summary

How does Zai Lab compare to ImmunityBio?

Does the media prefer IBRX or ZLAB?

Do institutionals & insiders believe in IBRX or ZLAB?

Which has better valuation & earnings, IBRX or ZLAB?

Is IBRX or ZLAB more profitable?

Which has more volatility & risk, IBRX or ZLAB?

Do analysts prefer IBRX or ZLAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZLAB vs. The Competition

Zai Lab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools